Evaluating Preoperative Stereotactic Body Radiotherapy Followed by Surgery for Spinal Metastases

What this Trial Is About

This research evaluates the use of preoperative hypofractionated Stereotactic Body Radiotherapy SBRT for patients undergoing surgery to treat spinal metastases, which are tumors that have spread to the spine from solid cancers. The study aims to determine if SBRT before surgery can control tumor growth at the affected spinal segments and improve postoperative outcomes such as pain, function, and quality of life. Participants will receive hypofractionated SBRT delivered in 1 to 3 sessions within one week after consenting, planned using MRI combined with CT scans and performed according to established institutional and ESTRO guidelines. Surgical treatment, which may include spinal canal decompression andor stabilization with instrumentation, will occur within 10 days following consent, tailored to the patients clinical needs. Throughout the study, participants will undergo MRI and CT scans before surgery, shortly after, and at 3 and 6 months post-surgery to assess tumor size and local control. They will complete questionnaires evaluating pain intensity, physical limitations, and overall quality of life. Researchers will also monitor wound healing, functional status, and any surgical instrumentation issues up to 6 months after treatment. The involvement includes preoperative and multiple follow-up assessments to measure safety and effectiveness outcomes over time.

Preoperative Stereotactic Radiotherapy for Treatment of Spinal Metastases